Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 82, Issue 1, Pages 70-80Publisher
WILEY
DOI: 10.1038/sj.clpt.6100223
Keywords
-
Categories
Funding
- NCI NIH HHS [CA81008, R01 CA106633-01, R01 CA106633-02, R01 CA106633, R01 CA106633-03, R01 CA106633-04, T32-CA09678, CA10663] Funding Source: Medline
Ask authors/readers for more resources
In vivo studies represent an essential step in drug development and currently rely largely on mice, yet limitations of mammalian models motivated the search for complementary vertebrate model systems. This review focuses on zebrafish, Danio rerio, as a facile model system to study human disease and drug responses. Zebrafish are particularly suited for this purpose because they represent a vertebrate species, their genome is sequenced, and a large number of synchronously developing, transparent embryos can be produced. Zebrafish embryos are permeable to drugs and can easily be manipulated using well-established genetic and molecular approaches. Here, we summarize recent work on drug discovery and toxicity in zebrafish embryos. In addition, we provide a synopsis of current efforts to establish disease models in zebrafish focusing on neoplasia. The results of these studies highlight the potential of zebrafish as a viable addition to established animal models by offering medium and, potentially, high throughput capabilities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available